Shivani Nanda
Impact in
Papers in
- Co-authors
- Bruce D. BartholowKenneth J. SherBeatrix BálintMark A. SocinskiRodryg RamlauNick ThatcherLuis Paz‐AresH. Depenbrock
- Journals
- Journal of Clinical Oncology (14 papers)Annals of Oncology (9 papers)Cancer Research (5 papers)Journal of Thoracic Oncology (3 papers)Nature Communications (2 papers)
- Partner nations
- United StatesGermanySpain
In The Last Decade
Shivani Nanda
57 papers receiving 951 citations
Hit Papers
Peers
Comparison fields: 5 of 102
- Aging 46
- Oncology 459
- Pulmonary and Respiratory Medicine 443
- Applied Psychology 57
- Cancer Research 131
Countries citing papers authored by Shivani Nanda
This map shows the geographic impact of Shivani Nanda's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shivani Nanda with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shivani Nanda more than expected).
Fields of papers citing papers by Shivani Nanda
This network shows the impact of papers produced by Shivani Nanda. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shivani Nanda. The network helps show where Shivani Nanda may publish in the future.
Co-authors
The 25 scholars most cited alongside Shivani Nanda, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2025 | 0 | |
| 3 | 2024 | 5 | |
| 4 | 2024 | 2 | |
| 5 | 2023 | 11 | |
| 6 | 2023 | 1 | |
| 7 | 2023 | 6 | |
| 8 | 2023 | 5 | |
| 9 | 2021 | 17 | |
| 10 | 2021 | 34 | |
| 11 | 2020 | 33 | |
| 12 | 2018 | 1 | |
| 13 | 2017 | 15 | |
| 14 | Proniosomes: A versatile drug delivery | 2016 | 1 |
| 15 | Efficacy and safety of necitumumab continuation therapy in phase 3 SQUIRE study | 2015 | 1 |
| 16 | 2015 | 3 | |
| 17 | Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial Hit paper breakdown → | 2015 | 331 |
| 18 | 2011 | 75 | |
| 19 | 2001 | 144 | |
| 20 | 1999 | 10 |
About Shivani Nanda
Shivani Nanda is a scholar working on Aging, Oncology, Pulmonary and Respiratory Medicine, Gastroenterology and Biochemistry, having authored 60 papers that have together received 978 indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (19 papers), Lung Cancer Research Studies (13 papers), Colorectal Cancer Treatments and Studies (12 papers), Advanced Breast Cancer Therapies (8 papers), Genetics, Aging, and Longevity in Model Organisms (7 papers), Colorectal and Anal Carcinomas (5 papers), HER2/EGFR in Cancer Research (5 papers) and Neuroendocrine Tumor Research Advances (5 papers). The work is most often cited by research in Aging (46 citations), Oncology (459 citations), Pulmonary and Respiratory Medicine (443 citations), Applied Psychology (57 citations) and Cancer Research (131 citations). Shivani Nanda has collaborated with scholars based in United States, Germany and Spain. Frequent co-authors include Bruce D. Bartholow, Kenneth J. Sher, Beatrix Bálint, Mark A. Socinski, Rodryg Ramlau, Nick Thatcher, Luis Paz‐Ares, H. Depenbrock, Tudor–Eliade Ciuleanu and Aleksandra Szczęsna. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Cancer Research, Journal of Thoracic Oncology and Nature Communications.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.